Trials / Completed
CompletedNCT04294147
A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist
A Phase 4 Single-Blind Study of Gastrointestinal Transit Time in Adult Patients With Migraine Before and After Initiation of a mAb CGRP Antagonist
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure the gastrointestinal emptying time using the wireless motility capsule (WMC) technology (FDA approved SmartPill™) in adult participants with migraine who are taking a monoclonal antibody (mAb) calcitonin gene-related peptide (CGRP) antagonist called galcanezumab or erenumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galcanezumab | Administered SC |
| DRUG | Erenumab | Administered SC |
Timeline
- Start date
- 2020-10-06
- Primary completion
- 2021-03-05
- Completion
- 2021-03-05
- First posted
- 2020-03-03
- Last updated
- 2022-03-22
- Results posted
- 2022-03-22
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04294147. Inclusion in this directory is not an endorsement.